ECSP066792A - Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c - Google Patents

Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c

Info

Publication number
ECSP066792A
ECSP066792A EC2006006792A ECSP066792A ECSP066792A EC SP066792 A ECSP066792 A EC SP066792A EC 2006006792 A EC2006006792 A EC 2006006792A EC SP066792 A ECSP066792 A EC SP066792A EC SP066792 A ECSP066792 A EC SP066792A
Authority
EC
Ecuador
Prior art keywords
cetoamids
hepatitis
virus
inhibitors
newly
Prior art date
Application number
EC2006006792A
Other languages
English (en)
Inventor
Viyyoor M Girijavallabhn
Frank Bennett
Stephane L Bogen
F George Njoroge
Ashok Arasappan
Kevin X Chen
Srikanth Venkatraman
Latha G Nair
Bancha Vibulbhan
Mousumi Sannigrahi
Weiying Yang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34919371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP066792A publication Critical patent/ECSP066792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención describe novedosos compuestos los cuales tienen actividad inhibitoria de la proteasa de VHC así como también métodos para preparar dichos compuestos. En otra realización, la invención describe composiciones farmacéuticas que comprenden ese tipo de compuestos así como también métodos para su utilización para tratar trastornos asociados con la proteasa de VHC.
EC2006006792A 2004-02-27 2006-08-25 Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c ECSP066792A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54850604P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ECSP066792A true ECSP066792A (es) 2006-11-16

Family

ID=34919371

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006792A ECSP066792A (es) 2004-02-27 2006-08-25 Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c

Country Status (18)

Country Link
US (2) US7173057B2 (es)
EP (1) EP1730142B1 (es)
JP (1) JP4874227B2 (es)
KR (1) KR20070026394A (es)
CN (1) CN1946718A (es)
AR (1) AR048023A1 (es)
AT (1) ATE514691T1 (es)
AU (1) AU2005219824B2 (es)
BR (1) BRPI0508217A (es)
CA (1) CA2557304C (es)
EC (1) ECSP066792A (es)
IL (1) IL177628A0 (es)
NO (1) NO20064355L (es)
PE (1) PE20050999A1 (es)
RU (1) RU2006134000A (es)
TW (1) TW200529822A (es)
WO (1) WO2005085242A1 (es)
ZA (1) ZA200607048B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8812150B2 (en) * 2003-11-10 2014-08-19 Brooks Automation, Inc. Semiconductor manufacturing process modules
US8696298B2 (en) * 2003-11-10 2014-04-15 Brooks Automation, Inc. Semiconductor manufacturing process modules
US10086511B2 (en) 2003-11-10 2018-10-02 Brooks Automation, Inc. Semiconductor manufacturing systems
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
US7192957B2 (en) * 2004-02-27 2007-03-20 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130687A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
CN101212970B (zh) * 2005-06-02 2010-07-21 先灵公司 Hcv蛋白酶抑制剂与表面活性剂的组合物
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
NZ563369A (en) * 2005-06-02 2011-03-31 Schering Corp Controlled-release formulation useful for treating disorders associated with hepatitus C virus
WO2006130554A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
GEP20104956B (en) 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AU2006315438A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2643680A1 (en) 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors and their uses
MX2008013125A (es) * 2006-04-11 2008-10-21 Novartis Ag Compuestos organicos y sus usos.
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
JP2010522172A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション Ｈｃｖｎｓ３プロテアーゼのｐ１−非エピメリ化ケトアミド阻害剤
MX2009010207A (es) * 2007-03-23 2009-10-19 Schering Corp Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
KR20100024920A (ko) * 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
MX2009012093A (es) 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
BRPI0817881A2 (pt) * 2007-10-10 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
KR20100118991A (ko) 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
KR20110005869A (ko) 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
WO2010080874A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
JP5565320B2 (ja) * 2011-01-06 2014-08-06 富士通株式会社 情報処理装置及び情報処理プログラム
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2709455A4 (en) * 2011-05-18 2014-11-05 Enanta Pharm Inc PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN104292130B (zh) * 2014-10-13 2016-04-27 苏州永健生物医药有限公司 一种波普瑞韦中间体2-羟基-3-氨基-4-环丁基丁酰胺盐酸盐的合成方法
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
JP7810788B2 (ja) * 2021-08-02 2026-02-03 北京華益健康薬物研究中心 コロナウイルス感染症の治療又は予防のための３ｃｌプロテア－ゼ小分子阻害剤及びその用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461293A (en) * 1982-12-03 1984-07-24 Kircaldie, Randall, And Mcnab Respirating gas supply method and apparatus therefor
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
NZ531681A (en) * 2001-10-24 2007-05-31 Vertex Pharma Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
AU2003207625B2 (en) * 2002-01-23 2006-09-07 Schering Corporation Proline compounds as NS3-serine protease inhibitors for use in treatment of hepatites C virus infection
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
JP2005173784A (ja) * 2003-12-09 2005-06-30 Nec Corp 映像情報配信システム及び方法と装置並びにプログラム
US7245891B2 (en) * 2003-10-21 2007-07-17 Kyocera Wireless Corp. Wireless mobile communication device having a speaker vibration alert and method of using same
ES2328589T3 (es) * 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease

Also Published As

Publication number Publication date
PE20050999A1 (es) 2005-12-01
WO2005085242A1 (en) 2005-09-15
EP1730142A1 (en) 2006-12-13
CN1946718A (zh) 2007-04-11
US20050222047A1 (en) 2005-10-06
NO20064355L (no) 2006-11-24
JP2007525518A (ja) 2007-09-06
EP1730142B1 (en) 2011-06-29
RU2006134000A (ru) 2008-04-10
ATE514691T1 (de) 2011-07-15
AU2005219824B2 (en) 2007-11-29
KR20070026394A (ko) 2007-03-08
ZA200607048B (en) 2008-06-25
BRPI0508217A (pt) 2007-07-17
AR048023A1 (es) 2006-03-22
US7619094B2 (en) 2009-11-17
US7173057B2 (en) 2007-02-06
AU2005219824A1 (en) 2005-09-15
TW200529822A (en) 2005-09-16
IL177628A0 (en) 2006-12-31
CA2557304C (en) 2013-08-06
JP4874227B2 (ja) 2012-02-15
US20070093430A1 (en) 2007-04-26
CA2557304A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
ECSP066795A (es) Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP034439A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
CL2012001230A1 (es) Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
ECSP034438A (es) Nuevos peptidos como inhibidores de ns-3-serina proteasa del virus de la hepatitis c
NI200900069A (es) Inhibidores de la proteasa ns3 del hcv
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
EA201171174A1 (ru) Ингибиторы репликации вируса гепатита c
MX2015007888A (es) Compuestos antivirales.
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
BRPI0508217A (pt) cetamidas com p4's cìclico como inibidores de ns3 serina protease de vìrus de hepatite c
ECSP088518A (es) Nucleósidos antivirales
EA200901241A1 (ru) Соединения для лечения гепатита с
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.